Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biosimilars

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

Washington, DC, September 7, 2017 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) in March 2016 launched a new section of our website today that provides educational resources on these topics. Continue reading

Trump Administration Seeks to Hike Life Sciences Industry’s FDA User Fees Paid to Help Review, Approve Medical Advancements

Washington, DC, April 20, 2017 — Thomas M. Burton reported in The Wall Street Journal that a bipartisan bill in Congress calls for sharp increases in user fees paid by medical industries to the Food and Drug Administration (FDA) to bear the cost of reviewing brand-name and generic drugs, medical devices and a type of generics called biosimilars.

The total base fees for prescription drugs to be collected for fiscal year 2018 under the legislation would be about $878.8 million, up 22% from the current fiscal year’s amount of $718.7 million, according to congressional aides.

The payments from industry have previously accounted for 70% of the FDA’s brand-name drug review budget, 36% of the medical device review budget, 75% of the budget for generic drug reviews and 29% of that for biosimilars, which mimic complex biological drugs. Continue reading

Pharmaceutical, Other Life Sciences Sectors Would Pay More FDA User Fees Under Bipartisan Bill

Washington, DC, April 17, 2017 — Thomas M. Burton reports in The Wall Street Journal that a bipartisan bill in Congress calls for sharp increases in user fees paid by medical industries to the Food and Drug Administration to bear the cost of reviewing brand-name and generic drugs, medical devices and a type of generics called biosimilars.

The total base fees for prescription drugs to be collected for fiscal year 2018 under the legislation would be about $878.8 million, up 22% from this fiscal year’s amount of $718.7 million, according to congressional aides. Continue reading

Generic Pharmaceutical Association Changes Name to Association for Accessible Medicines; Launches Education Campaign

Washington, DC, February 22, 2017 — The Generic Pharmaceutical Association (GPhA), the nation’s largest trade group representing generic pharmaceutical and biosimilar companies, on February 14 week unveiled a new national effort to contain the cost of prescription medicines.

The group is becoming the Association for Accessible Medicines (AAM) to communicate its mission to make more medicines more accessible to more people who need them. Continue reading

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

phrma-logo-whiteWashington, DC, October 17, 2016 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a new section of our website today that provides educational resources on these topics. Continue reading

IMS Institute Report: Biosimilar Drugs Could Save Up to $110 Billion by 2020

R&D 1London, England, March 30, 2016 ― Ben Hirschler reports for Reuters that lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as 98 billion euros ($110 billion) by 2020, according to a new analysis by IMS Institute for Healthcare Informatics said.

Realizing those savings, however, depends on effective doctor education and healthcare providers adopting smart market access strategies, the report said.

A saving of 98 billion euros is based on eight major branded biotech drugs, including AbbVie’s Humira and Roche’s Herceptin, that are set to lose patent protection over the next five years. Continue reading

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

PhRMA jpgWashington, DC, March 27, 2016 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a new section of our website today that provides educational resources on these topics. Continue reading

PhRMA Launches Biologics and Biosimilars Online Resources

Pills red white blueWashington, DC, January 31, 2016 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a new section of our website today that provides educational resources on these topics. Continue reading

PhRMA Launches Biologics and Biosimilars Online Resources

PhRMA jpgWashington, DC, December 19, 2015 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) is excited to launch a new section of our website today that provides educational resources on these topics. Continue reading

Governor Christie Signs Biosimilars Legislation

Chris Christie official portrait 2013Trenton, NJ, November 10, 2015 ― Legislation sponsored by Assembly Democrats Pamela Lampitt, Herb Conaway, Jr., M.D., Daniel Benson, Shavonda Sumter and Nancy Pinkin to make it easier for consumers to obtain more cost-effective, “generic” versions of biological medicines used to treat conditions such as rheumatoid arthritis, anemia, psoriasis and various forms of cancer has been signed into law.

“The FDA has created a safe pathway to make alternative biological medicines more readily available on the market,” said Lampitt (D-Camden, Burlington). “If there is a more cost-effective option to treat and cure various illnesses, then by all means we should be helping patients pursue it.” Continue reading